We made it to the end of another series. In our FINAL episode of the prostate cancer series, we turn our attention to metastatic castrate-resistant prostate cancer! We discuss treatment options, the data behind why we do what we do, and more targeted agents.Content: - Approach to metastatic castrate-resistant prostate cancer- Refresher on what it means to be castrate-resistant - Role of bisphosphate therapy and denosumab- Treatment options and data surrounding sequencing of agents - Other options for prostate cancer (radium-223 and lutetium-177-PSMA-617)- Role of PARP inhibitors in BRCA-mutated disease ** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodesLove what you hear? Tell a friend and leave a review on our podcast streaming platforms!Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Google Podcast

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related